| pubmed-article:10742586 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0006938 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0010558 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0475370 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0598629 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0868939 | lld:lifeskim |
| pubmed-article:10742586 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:10742586 | pubmed:issue | 2-3 | lld:pubmed |
| pubmed-article:10742586 | pubmed:dateCreated | 2000-8-2 | lld:pubmed |
| pubmed-article:10742586 | pubmed:abstractText | Parent beta-cyclodextrin (beta-CyD) and 2-hydroxypropyl-beta-CyD (HP-beta-CyD) form 1:1 solid complexes with an orally active angiotensin-converting enzyme inhibitor, captopril, while hydrophobic perbutanoyl-beta-CyD (TB-beta-CyD) forms a solid dispersion or solid solution with the drug. The binary system of captopril/HP-beta-CyD or captopril/TB-beta-CyD and the ternary system of captopril/TB-beta-CyD/HP-beta-CyD in different molar ratios were prepared by the kneading method, and the release behavior of the drug was investigated. The release rate of captopril from the binary HP-beta-CyD system was rather fast, whereas that from the binary TB-beta-CyD system was comparatively slower, the retarding effect being dependent on the amounts of TB-beta-CyD. The release rate from the ternary captopril/TB-beta-CyD/HP-beta-CyD system was slowed down by the addition of small amounts of HP-beta-CyD, whereas the rate became faster as the molar ratio of HP-beta-CyD further increased (>.25 molar ratio). Both water penetration studies and microscopic observation suggested that the retarding effect is attributable to a gel formation of HP-beta-CyD in the TB-beta-CyD hydrophobic matrix. It was difficult to prolong plasma levels of captopril by administering orally either the binary HP-beta-CyD or TB-beta-CyD system in dogs. On the other hand, the ternary captopril/TB-beta-CyD/HP-beta-CyD system (molar ratio of 1:0.5:0.5) gave a plasma profile comparable to that of a commercially available sustained release preparation (Captoril R). Therefore, a combination of HP-beta-CyD and TB-beta-CyD is useful for the controlled release of water-soluble drugs such as captopril. | lld:pubmed |
| pubmed-article:10742586 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10742586 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10742586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10742586 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10742586 | pubmed:month | May | lld:pubmed |
| pubmed-article:10742586 | pubmed:issn | 0168-3659 | lld:pubmed |
| pubmed-article:10742586 | pubmed:author | pubmed-author:KimuraKK | lld:pubmed |
| pubmed-article:10742586 | pubmed:author | pubmed-author:IkedaYY | lld:pubmed |
| pubmed-article:10742586 | pubmed:author | pubmed-author:ArimaHH | lld:pubmed |
| pubmed-article:10742586 | pubmed:author | pubmed-author:UekamaKK | lld:pubmed |
| pubmed-article:10742586 | pubmed:author | pubmed-author:HirayamaFF | lld:pubmed |
| pubmed-article:10742586 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10742586 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10742586 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:10742586 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10742586 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10742586 | pubmed:pagination | 271-80 | lld:pubmed |
| pubmed-article:10742586 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:meshHeading | pubmed-meshheading:10742586... | lld:pubmed |
| pubmed-article:10742586 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10742586 | pubmed:articleTitle | Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives. | lld:pubmed |
| pubmed-article:10742586 | pubmed:affiliation | Wakunaga Pharmaceutical Co., 1624 Shimokotachi, Kodacho, Takata-gun, Hiroshima, Japan. | lld:pubmed |
| pubmed-article:10742586 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10742586 | lld:pubmed |
